α‐Asarone alleviates allergic asthma by stabilizing mast cells through inhibition of ERK/JAK2‐STAT3 pathway.

Asthma is a heterogeneous disease related to numerous inflammatory cells, among which mast cells play an important role in the early stages of asthma. Therefore, treatment of asthma targeting mast cells is of great research value. α‐Asarone is an important anti‐inflammatory component of the traditional Chinese medicine Acorus calamus L, which has a variety of medicinal values. To investigate whether α‐asarone can alleviate asthma symptoms and its mechanism. In this study, we investigated the effect of α‐asarone on mast cell activation in vivo and in vitro. The release of chemokines or cytokines, AHR (airway hyperresponsiveness), and mast cell activation were examined in a mast cell‐dependent asthma model. Western blot was performed to determine the underlying pathway. α‐Asarone inhibited the degranulation of LAD2 (laboratory allergic disease 2) cells and decreased IL‐8, MCP‐1, histamine, and TNF‐α in vitro. α‐Asarone reduced paw swelling and leakage of Evans blue, as well as serum histamine, CCL2, and TNF‐α in vivo. In the asthma model, α‐asarone showed an inhibitory effect on AHR, inflammation, mast cells activation, infiltration of inflammatory cells, and the release of IL‐5 and IL‐13 in lung tissue. α‐Asarone decreased the levels of phosphorylated JAK2, phosphorylated ERK, and phosphorylated STAT3 induced by C48/80. Our findings suggest that α‐asarone alleviates allergic asthma by inhibiting mast cell activation through the ERK/JAK2‐STAT3 pathway. [ABSTRACT FROM AUTHOR]